Clinical trials: Diabetic Ulcer
Diabetic Foot Ulcers
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.
- Trial name
- NCT00563394
- Testing
- ofloxacin, MSI-78
- Where
- United States
- Volunteers
- 584 people
- Sponsor
- Abeona Therapeutics, Inc
Diabetic Foot Ulcer
A Controlled Prospective Treatment Study to Evaluate the Efficacy of Vendaje.
The Goal of this study is to evaluate the wound volume reduction rate and the time to closure when using Vendaje to manage diabetic wounds. The participants will be treated weekly for up to 12 weeks.
- Trial name
- NCT06150209
- Testing
- Vendaje
- Sponsor
- BioStem Technologies
Chronic Ulcers: Non-healing Deep Cavity Wounds (e.g., Diabetic Foot Ulcers, Arterial Ulcers, Post-surgical Wound Healing Disorders)
INJECTHEAL - Investigation of Chronic Wound Exudate and Biofilm
This prospective observational study will collect routine clinical waste material from 72 adults with chronic, non-healing wounds, including wound exudate from negative pressure therapy containers or sponges and wound…
- Trial name
- INJECTHEAL (NCT07745764)
- Testing
- standard of care
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Barbara Wolff-Winiski
Diabetic Foot Ulcer, Diabetic Foot Ulcer (DFU)
Study to Assess Remote Imaging System to Monitor Diabetic Foot Ulcers
The goal of this observational pilot study is to evaluate whether a new remote monitoring platform (TASHA) can support accurate and reliable assessment of diabetic foot ulcers in adult patients receiving care in a UK NHS clinic.
- Trial name
- NCT07013448
- Testing
- Foot scan
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Medical Intelligence Group
Diabetic Foot Infection
Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers
The purpose of this study is to establish the clinical superiority and the safety of topical pexiganan cream 0.8% plus standard local wound care, as compared to placebo cream plus standard local wound care, in the treatment of…
- Trial name
- OneStep-1 (NCT01590758)
- Testing
- Topical pexiganan cream 0.8%, Standard wound care
- Where
- 30 sites in United States
- Volunteers
- 189 people
- Sponsor
- Dipexium Pharmaceuticals, Inc.
Diabetic Foot Ulcer, Diabetic Foot Infection
Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foot Ulcer
This clinical trial evaluates the safety and efficacy of the Nanordica Advanced Antibacterial Wound Dressing (AAWD) in patients suffering from diabetic foot ulcers.
- Trial name
- NM2023 (NCT06667752)
- Testing
- Advanced Antibacterial Wound Dressing, Aquacel Ag+ Extra
- Where
- 11 sites in Estonia, Spain
- Volunteers
- 136 people
- Sponsor
- Nanordica Medical OU
Wounds and Injuries, Diabetes
Gene Therapy to Improve Wound Healing in Patients With Diabetes
Patients with diabetes may develop chronic wounds that respond poorly to treatment. Gene therapy with the platelet-derived growth factor-B gene has been shown to help with the healing of chronic wounds.
- Conditions
- Wounds and Injuries, Diabetes, Diabetic Foot Ulcers, Foot Wounds
- Trial name
- NCT00065663
- Testing
- GAM501
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tissue Repair Company
Pressure Ulcer, Arterial Ulcers
Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
The aim of this post market clinical follow up (PMCF) study is to confirm the performance of Suprasorb® A + Ag wound dressing and rope, to collect safety data regarding expected adverse events and to detect potential unexpected…
- Conditions
- Pressure Ulcer, Arterial Ulcers, Venous Leg Ulcer, Diabetic Ulcers
- Trial name
- NCT05646121
- Testing
- Suprasorb® A + Ag wound dressing and rope
- Where
- 8 sites in Poland
- Volunteers
- 99 people
- Sponsor
- Lohmann & Rauscher
Diabetic Foot Ulcer
A Two-Part, Randomized Study of Dermacyte® Amniotic Wound Care Matrix
This is a multi-center, prospective, two-part, controlled study to determine the percentage of participants with complete ulcer closure of a target DFU at Week 12 following treatment with Dermacyte Matrix or SOC.
- Trial name
- NCT06444906
- Testing
- Dermacyte Matrix, Standard of Care (SOC)
- Volunteers
- 85 people
- Sponsor
- Merakris Therapeutics
Wounds, Leg Ulcers
The AutoloGel™ Post-Market Surveillance (TAPS) Program
AutoloGel™ Post-Market Surveillance Program Purpose:Evaluate the incidence of hematologic and immunologic adverse events, including coagulopathies in patients with wounds to which AutoloGel™ was applied.
- Conditions
- Wounds, Leg Ulcers, Pressure Ulcers, Diabetic Foot Ulcers
- Trial name
- TAPS (NCT00762138)
- Testing
- AutoloGel System
- Where
- 2 sites in United States
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Cytomedix
Diabetic Foot Ulcer
Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer
The purpose of this study is to determine whether the gentamicin-collagen sponge when combined with standard of daily wound care is safe and effective in treating mildly infected skin ulcers compared to treatment with an oral…
- Trial name
- NCT00593567
- Testing
- gentamicin-collagen sponge, Levofloxacin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Innocoll
Diabetic Foot Ulcer
FeetSee Thermal Images Collection Protocol in Diabetes Patients
Diabetic foot ulcers (DFUs) are a major cause of morbidity, lower-extremity amputation and healthcare costs in people with diabetes.
- Trial name
- NCT07300163
- Testing
- FeetSee thermal camera
- Where
- 4 sites in Lithuania, United Kingdom
- Volunteers
- 100 people
- Sponsor
- Diabetis JSC
Non Healing Diabetic Foot Ulcer
Comparing Wound Area Reduction of Non-healing DFUs Using MolecuLight i:X Versus Standard of Care
This is a 12 week, randomized controlled trial. There are 2 arms and 20 patients with non healing diabetic foot ulcer allocated in each arm.
- Trial name
- WAR (NCT04207099)
- Testing
- MolecuLight i:X Imaging Device
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- MolecuLight Inc.
Infection; Diabetic Foot
Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)
This study compared ertapenem sodium to piperacillin/tazobactam sodium for the treatment of moderate to severe diabetic foot infections.
- Trial name
- NCT01370616
- Testing
- Ertapenem sodium, Piperacillin/tazobactam sodium, Amoxicillin/clavulunate potassium
- Volunteers
- 565 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Foot Ulcer (DFU), Ulcer Foot
Modified Platform Trial Assessing Multiple Umbilical Cord-based CAMPs and SOC v SOC Alone in the Treatment of Hard-to-Heal DFUs
The purpose of this study is to evaluate the efficacy of two dehydrated human umbilical cord-based medical devices, also defined as Cellular, Acellular, Matrix-like Products/skin substitutes, plus SOC versus SOC alone in…
- Conditions
- Diabetic Foot Ulcer (DFU), Ulcer Foot, Diabetic Foot, Foot Ulcer
- Trial name
- CORDSTIM-DFU (NCT07449975)
- Testing
- Standard of Care (SOC), Corplex P, Theracor
- Volunteers
- 272 people
- Sponsor
- StimLabs
Diabetic Foot Ulcer, Venous Leg Ulcer
Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)
In participants with diabetic foot ulcers (DFUs), this study will assess complete wound closure by comparing synthetic hybrid-scale fiber matrix (Restrata®) with standard of care.
- Trial name
- NCT04927702
- Testing
- Synthetic Hybrid-Scale Fiber Matrix, Standard of Care, Living Cellular Skin Substitute
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Acera Surgical, Inc.
Diabetic Foot Ulcer
Assessment of the Efficacy and Safety of a New Medical Device in the Local Treatment of Diabetic Foot Ulcers
Evaluation of the efficacy and safety of a device with LU3103209 compound versus the same device, free of LU3103209 compound, in the local management of DFUs.
- Trial name
- DISCOVERY (NCT03110796)
- Testing
- Dressing with LU3103209 - Dose 1, Dressing with LU3103209 - Dose 2, Dressing without LU3103209
- Where
- 6 sites in Czechia, France and 4 more
- Volunteers
- 210 people
- Sponsor
- Laboratoires URGO
Diabetic Foot Ulcers
MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers
224 adults with diabetic foot ulcers will be randomized to either magainin peptide (MSI-78) or ofloxacin (FLOXIN, Ortho-McNeil Pharmaceutical Corporation) an oral fluoroquinolone antibiotic.
- Trial name
- NCT00563433
- Testing
- ofloxacin, MSI-78
- Where
- United States
- Volunteers
- 342 people
- Sponsor
- Abeona Therapeutics, Inc